MA37664A1 - Formulation pour implant contenant de la rispéridone et/ou de la palipéridone - Google Patents

Formulation pour implant contenant de la rispéridone et/ou de la palipéridone

Info

Publication number
MA37664A1
MA37664A1 MA37664A MA37664A MA37664A1 MA 37664 A1 MA37664 A1 MA 37664A1 MA 37664 A MA37664 A MA 37664A MA 37664 A MA37664 A MA 37664A MA 37664 A1 MA37664 A1 MA 37664A1
Authority
MA
Morocco
Prior art keywords
paliperidone
risperidone
weeks
formulation containing
lactic acid
Prior art date
Application number
MA37664A
Other languages
English (en)
Other versions
MA37664B1 (fr
Inventor
Aduriz Ibon Gutierro
Rodriguez Guillermo Franco
Original Assignee
Farmacéuticos Rovi S A Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46147376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37664(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Farmacéuticos Rovi S A Lab filed Critical Farmacéuticos Rovi S A Lab
Publication of MA37664A1 publication Critical patent/MA37664A1/fr
Publication of MA37664B1 publication Critical patent/MA37664B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Cette invention concerne une composition retard injectable par voie intramusculaire adaptée à former in situ un implant solide dans le corps. La composition comprend de la rispéridone et/ou de la palipéridone (médicaments) et/ou l'un quelconque de leurs sels pharmaceutiques acceptables, quelle que soit leur combinaison, un copolymère biocompatible à base d'acide lactique et d'acide glycolique dont le rapport monomère acide lactique sur acide glycolique se situe dans la plage 50:50, et du dmso pour solvant. La composition libère la rispéridone et/ou de la palipéridone immédiatement et en continu pendant au moins 4 semaines, son profil pharmacocinétique in vivo permettant que la formulation soit administrée toutes les 4 semaines ou sur des périodes plus longues.
MA37664A 2012-05-31 2014-12-16 Formulation pour implant contenant de la rispéridone et/ou de la palipéridone MA37664B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12170362.3A EP2529756B1 (fr) 2011-05-31 2012-05-31 Formulation d'implant de rispéridone et/ou de palipéridone
PCT/EP2013/061320 WO2013178812A1 (fr) 2012-05-31 2013-05-31 Formulation pour implant contenant de la rispéridone et/ou de la palipéridone

Publications (2)

Publication Number Publication Date
MA37664A1 true MA37664A1 (fr) 2016-03-31
MA37664B1 MA37664B1 (fr) 2016-11-30

Family

ID=46147376

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37664A MA37664B1 (fr) 2012-05-31 2014-12-16 Formulation pour implant contenant de la rispéridone et/ou de la palipéridone

Country Status (30)

Country Link
EP (2) EP2529756B1 (fr)
JP (1) JP6367795B2 (fr)
KR (1) KR101880716B1 (fr)
CN (1) CN104363923A (fr)
AU (1) AU2013269547B2 (fr)
BR (1) BR112014029209A2 (fr)
CA (1) CA2874765C (fr)
CL (1) CL2014003216A1 (fr)
CO (1) CO7160108A2 (fr)
CY (1) CY1124369T1 (fr)
DK (1) DK2529756T3 (fr)
EA (1) EA031819B1 (fr)
ES (1) ES2878112T3 (fr)
HR (1) HRP20211057T1 (fr)
IL (1) IL235849B (fr)
IN (1) IN2014DN10672A (fr)
LT (1) LT2529756T (fr)
MA (1) MA37664B1 (fr)
MX (1) MX2014014483A (fr)
MY (1) MY174999A (fr)
NZ (1) NZ703321A (fr)
PH (1) PH12014502667A1 (fr)
PL (1) PL2529756T3 (fr)
PT (1) PT2529756T (fr)
RS (1) RS62059B1 (fr)
SG (1) SG11201407961WA (fr)
SI (1) SI2529756T1 (fr)
UA (1) UA119430C2 (fr)
WO (1) WO2013178812A1 (fr)
ZA (1) ZA201409299B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
CN101801415B (zh) 2007-05-25 2015-09-23 Rb医药品有限公司 利培酮化合物的持续递送制剂
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
EP2394664B1 (fr) 2010-05-31 2016-06-01 Laboratorios Farmaceuticos Rovi, S.A. Compositions pour implants biodégradables in situ injectables
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
PL2394663T3 (pl) 2010-05-31 2022-02-21 Laboratorios Farmaceuticos Rovi, S.A. Kompozycje do wstrzykiwania implantów biodegradowalnych in-situ
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
DK2529756T3 (da) * 2011-05-31 2021-08-02 Farm Rovi Lab Sa Risperidon- og/eller paliperidon-implantatformulering
SI2529757T1 (sl) * 2011-05-31 2014-05-30 Laboratorios Farmaceuticos Rovi, S.A. Formulacija paliperidon implantata
CN109602692B (zh) 2013-03-11 2022-11-04 度瑞公司 包含高粘度液体载体的可注射控制释放组合物
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
CN104922085B (zh) * 2015-06-01 2016-10-26 湖南赛沃药业有限公司 一种利培酮植入剂及其制备方法
CN109589304A (zh) * 2017-10-01 2019-04-09 万特制药(海南)有限公司 利培酮口服溶液及其制备方法
MX2020012459A (es) 2018-05-24 2021-04-28 Celanese Eva Performance Polymers Llc Dispositivo implantable para liberacion sostenida de un compuesto de farmaco macromolecular.
JP2021524841A (ja) 2018-05-24 2021-09-16 セラニーズ・イーブイエイ・パフォーマンス・ポリマーズ・エルエルシー 高分子薬剤化合物の持続放出用の埋め込み型デバイス
TW202313047A (zh) 2021-09-21 2023-04-01 西班牙商禾霏藥品實驗室有限公司 抗精神病可注射儲積型組合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3645906B2 (ja) 1993-11-19 2005-05-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ マイクロカプセル封入された3−ピペリジニル−置換1,2−ベンズイソオキサゾール類及び1,2−ベンズイソチアゾール類
WO2004064752A2 (fr) * 2003-01-22 2004-08-05 Alkermes Controlled Therapeutics, Inc. Procede de preparation de microparticules a liberation prolongee
CA2819769C (fr) * 2003-07-18 2016-06-28 Oakwood Laboratories, L.L.C. Methode pour empecher la perte de poids moleculaire des polymeres, la formation d'impuretes et la gelification dans les composes polymeriques
EP1802286B1 (fr) 2004-08-04 2008-07-23 ALZA Corporation Composition de liberation soutenue de medicament manifestant un schema de liberation d'ordre croissant nul, procedes de fabrication d'une telle composition
BRPI0809837A2 (pt) 2007-04-19 2014-11-11 Youxin Li "composto para tratamento de distúrbios mentais, saldo do composto para tratamento de distúrbios mentais, composição farmacéutica e uso do composto para tratamento de distúrbios mentais"
EP3115038A1 (fr) * 2007-05-18 2017-01-11 DURECT Corporation Formulations à dépôt amélioré
CN101801415B (zh) * 2007-05-25 2015-09-23 Rb医药品有限公司 利培酮化合物的持续递送制剂
WO2009015828A1 (fr) 2007-07-27 2009-02-05 Synthon B.V. Dérivés de palipéridone
US9439906B2 (en) 2007-12-19 2016-09-13 Janssen Pharmaceutica Nv Dosing regimen associated with long acting injectable paliperidone esters
US8758780B2 (en) 2009-10-06 2014-06-24 Ascendis Pharma As Subcutaneous paliperidone composition
EP2394664B1 (fr) * 2010-05-31 2016-06-01 Laboratorios Farmaceuticos Rovi, S.A. Compositions pour implants biodégradables in situ injectables
PL2394663T3 (pl) * 2010-05-31 2022-02-21 Laboratorios Farmaceuticos Rovi, S.A. Kompozycje do wstrzykiwania implantów biodegradowalnych in-situ
DK2529756T3 (da) * 2011-05-31 2021-08-02 Farm Rovi Lab Sa Risperidon- og/eller paliperidon-implantatformulering
SI2529757T1 (sl) * 2011-05-31 2014-05-30 Laboratorios Farmaceuticos Rovi, S.A. Formulacija paliperidon implantata

Also Published As

Publication number Publication date
PT2529756T (pt) 2021-07-28
ZA201409299B (en) 2015-12-23
SG11201407961WA (en) 2014-12-30
CA2874765C (fr) 2020-06-02
BR112014029209A2 (pt) 2017-06-27
HRP20211057T1 (hr) 2021-10-01
WO2013178812A1 (fr) 2013-12-05
RS62059B1 (sr) 2021-07-30
MX2014014483A (es) 2015-02-24
UA119430C2 (uk) 2019-06-25
EP2529756B1 (fr) 2021-05-19
LT2529756T (lt) 2021-07-26
CO7160108A2 (es) 2015-01-15
MA37664B1 (fr) 2016-11-30
PL2529756T3 (pl) 2021-11-15
IL235849A0 (en) 2015-01-29
IL235849B (en) 2019-03-31
KR20150016964A (ko) 2015-02-13
CY1124369T1 (el) 2022-07-22
AU2013269547A1 (en) 2015-01-22
CA2874765A1 (fr) 2013-12-05
IN2014DN10672A (fr) 2015-08-28
NZ703321A (en) 2017-01-27
EA031819B1 (ru) 2019-02-28
CL2014003216A1 (es) 2015-07-10
EP2529756A3 (fr) 2013-08-07
KR101880716B1 (ko) 2018-08-17
EP2529756A2 (fr) 2012-12-05
DK2529756T3 (da) 2021-08-02
JP2015518036A (ja) 2015-06-25
PH12014502667B1 (en) 2015-02-02
EA201401346A1 (ru) 2015-04-30
JP6367795B2 (ja) 2018-08-01
SI2529756T1 (sl) 2021-09-30
EP2854858A1 (fr) 2015-04-08
MY174999A (en) 2020-06-01
ES2878112T3 (es) 2021-11-18
PH12014502667A1 (en) 2015-02-02
CN104363923A (zh) 2015-02-18
AU2013269547B2 (en) 2018-03-15

Similar Documents

Publication Publication Date Title
MA37664B1 (fr) Formulation pour implant contenant de la rispéridone et/ou de la palipéridone
MA37661B1 (fr) Formulation pour implant contenant de la palipéridone
EP4344702A3 (fr) Dérivés de pyrazolyle utiles en tant qu'agents anticancéreux
EP4292588A3 (fr) Administration d'agents de potentialisation de cftr modifiés au deutérium
MA34296B1 (fr) Composition retard injectable antipsychotique
RS53205B (en) IMPLANTABLE PALIPERIDON FORMULATION
CY1112499T1 (el) Φαρμακευτικες συνθεσεις ενος νευροδραστικου στεροειδους και χρησεις αυτων
SI2600851T1 (en) PHARMACEUTICAL FORM OF DOSAGE COVERING 6'-FLUORO- (N-METHYLLINE N, N-DIMETHYL-4-PHENYL-4 ', 9'-DIHYDRO-3'H-SPIRO- (CYCLOHEXANE-1,1'- PIRANO (3,4, B) INDOL) -4-AMIN, FOR NON-PROPHETIC DISEASE TREATMENT
RU2014102940A (ru) Композиция противораковой вакцины, содержащая пептид wt1, для трансдермального введения
DK2579874T3 (da) Injicerbar, flydende sammensætning omfattende buprenorphin
PL1931316T5 (pl) Kompozycje farmaceutyczne o kontrolowanym uwalnianiu dla leków labilnych kwasowo
JP2010530376A5 (fr)
EP1864976A4 (fr) Dérivé de propane-1,3-dione ou sel de celui-ci
MX2019001596A (es) Uso y dosificacion de agentes terapeuticos para endometriosis.
MA53927B1 (fr) Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel
MA49557B1 (fr) Formulations à action prolongée
FR3054134B1 (fr) Formulation pharmaceutique de cineol et d'amoxicilline
SA520411067B1 (ar) تركيبات صلبة فموية من بيتا هستين ممتدة الإطلاق غير نابضة
MA39084A1 (fr) Formulation pharmaceutique de cineol et d'amoxicilline
MA40372B1 (fr) Formulation pharmaceutique de cineol et d'amoxicilline
TN2013000480A1 (fr) Composition pharmaceutique effervescente à base de sildénafil et son procédé de fabrication
TH148327B (th) อนุพันธ์เฮเทอโรไซคลิกและยาทางเภสัชกรรม